

Special Issue

Resistance to Therapy in Liver and Gastrointestinal Tumors

Message from the Guest Editors

Resistance to chemotherapy is a major problem for patients with most types of liver and gastrointestinal cancers (LGICs). Tumor cells can be resistant to chemotherapy before the administration of drugs (intrinsic resistance) or can be initially sensitive to drugs and develop resistance during treatment. The mechanisms behind the failure of chemotherapy include changes in transport proteins involved in drug uptake and efflux, changes in enzymes responsible for drug metabolism, mutations in drug targets, enhanced DNA repair damage, activation of survival-signaling pathways, the effect of factors related to tumor cell microenvironment, or the activation of epithelial–mesenchymal transition. This Special Issue aims to compile original research and review articles dealing with advances taking place in the area of chemoresistance research in LGICs, with special interest in articles describing mechanisms of resistance to treatments, identification of biomarkers associated with response to therapy, experimental models to study drug resistance, prognostic factors, strategies to overcome drug resistance, treatments based on molecular targets, and novel drug development.

Guest Editors

Prof. Dr. Rocio I.R. Macias

Prof. Oscar Briz

Prof. Dr. Jose J.G. Marin

Deadline for manuscript submissions

closed (31 July 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/37808

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)